Valuation We all know that a catch-up in market valuation will come soon.
Oncology stocks, once valuation is unlock, get the highest valuation of any medecine fields.
Just to show how undervalued we are at the moment, Belly's Pharma, which is only a one-indication stock (A Leader in the Development of The Novel P2X3 Antagonist Class Targeting Cough and Other Hypersensitization Disorders) and is expected to be granted FDA approval, is now valued at 1.7B$CAN.
Our turn is soon coming. We now have clinical data to apply for FDA designation(s), CR% and DR% superior to Keytruda, low side-effect treatment, high QOL treatmen, low number of treatments, management that has put their own money into the stock, that also participated in 2 pps and have been granted stock options and we have a "commercial revenue (projected)" milestone that is planned for early 2023 and that seems to be associated to a potential Accelerated Approval program, plus a FDA's response planned approx. around late February for the Breakthrough Therapy designation. And an industry that has guidelines on how much pivotal Ph. 2 data can be worth. Not to mention a 2nd PDC (Rutherrin) that is more potent than our current PDC (TLD1433) and that aims at 2 tough indications; NSCLC and GBM.
Valuation should start kicking on granting of FDA designation(s), possible jv offer, etc ...